Li Zhaoyang, Duan Zhicheng, Yang Huitang, Li Meng, Cai Yandong, Jiang Zhan, Fan Guoju, Wang Kaiqiang, Chen Bo, Zhang Hongwei, Li Yankui
Department of Vascular Surgery, The Second Hospital of Tianjin Medical University, Tianjin, China.
Center for Cardiovascular Diseases, The Second Hospital of Tianjin Medical University, Tianjin, China.
Vascular. 2024 Oct 12:17085381241289825. doi: 10.1177/17085381241289825.
To analyze the treatment methods and efficacy of inferior vena cava filter thrombosis (IVCFT).
In this retrospective study, the clinical data for 47 patients with IVCFT who underwent sequential treatment at the Department of Vascular Surgery, Tianjin Medical University Second Hospital, from January 2020 to January 2023 were analyzed. Patients were divided into three groups according to the treatment method: anticoagulant therapy (AC group), anticoagulation plus catheter-directed thrombolysis (CDT group), and anticoagulation plus AngioJet thrombectomy plus catheter-directed thrombolysis (PCDT group). The evaluation criteria for efficacy mainly included preoperative and postoperative clinical symptoms (Villalta score), thrombus diameter, thrombus clearance rate, filter retrieval rate, filter retention time, and urokinase dosage.
This study included 47 patients, of whom 31 were males (65.9%) and 16 females (34.1%), with a mean age of 72.05 ± 8.32 years. An Aegisy filter was used in seven patients, whereas an Illicium filter was used in forty patients. There were a total of nineteen patients in the anticoagulation-only group, with complete dissolution of the intraluminal thrombus in five patients, a residual thrombus with a maximum diameter ≤1 cm in three patients, and a residual thrombus with a maximum diameter >1 cm in eleven patients. The Villalta score was 7.16 ± 0.6 before treatment and decreased to 3.79 ± 0.59 after treatment. The thrombus diameter decreased from an average of 1.46 ± 0.2 cm before treatment to an average of 0.85 ± 0.14 cm after treatment. The retrieval rate for the filters was 42.11% (8/19), with an average dwell time of 27.4 ± 1.3 days for the filters. The CDT group consisted of 17 patients. Among whom we observed, complete dissolution of the intraluminal thrombus was observed in six patients, residual thrombus with a maximum diameter ≤1 cm in nine patients, and residual thrombus with a maximum diameter >1 cm in two patients. The Villalta score decreased from 7.53 ± 0.83 before treatment to 2.06 ± 0.39 after treatment. The thrombus diameter also decreased from 1.46 ± 0.16 cm before treatment to 0.35 ± 0.11 cm after treatment. The retrieval rate of the filters was 88.24% (15/17), and the average filter indwelling time was 19.25 ± 4.5 days. The PCDT group consisted of 11 patients. We observed complete dissolution of the intraluminal thrombus in four patients, residual thrombus with a maximum diameter ≤1 cm in six patients, and residual thrombus with a maximum diameter >1 cm in one patient. The Villalta score decreased from 7.45 ± 0.76 before treatment to 2.09 ± 0.55 after treatment. The thrombus diameter decreased from 1.50 ± 0.21 cm before treatment to 0.33 ± 0.35 cm after treatment, and the rate of filter retrieval was 90.91% (10/11).
The three treatments of anticoagulation therapy, CDT, and PCDT were meaningful for preoperative and postoperative thrombolysis and symptom improvement in patients with IVCFT. The application of CDT and PCDT was superior to anticoagulation therapy, while there was no significant difference between the CDT and PCDT group. The retrieval rate of filters in the anticoagulation therapy group was the lowest, with no significant difference between the CDT and PCDT group.
分析下腔静脉滤器血栓形成(IVCFT)的治疗方法及疗效。
本回顾性研究分析了2020年1月至2023年1月在天津医科大学第二医院血管外科接受序贯治疗的47例IVCFT患者的临床资料。根据治疗方法将患者分为三组:抗凝治疗组(AC组)、抗凝联合导管直接溶栓组(CDT组)和抗凝联合AngioJet血栓切除术及导管直接溶栓组(PCDT组)。疗效评估标准主要包括术前和术后临床症状(Villalta评分)、血栓直径、血栓清除率、滤器取出率、滤器留置时间及尿激酶用量。
本研究共纳入47例患者,其中男性31例(65.9%),女性16例(34.1%),平均年龄72.05±8.32岁。7例患者使用Aegisy滤器,40例患者使用Illicium滤器。单纯抗凝组共19例患者,5例患者腔内血栓完全溶解,3例患者残留血栓最大直径≤1cm,11例患者残留血栓最大直径>1cm。治疗前Villalta评分为7.16±0.6,治疗后降至3.79±0.59。血栓直径从治疗前的平均1.46±0.2cm降至治疗后的平均0.85±0.14cm。滤器取出率为42.11%(8/19),滤器平均留置时间为27.4±1.3天。CDT组共17例患者,其中6例患者腔内血栓完全溶解,9例患者残留血栓最大直径≤1cm,2例患者残留血栓最大直径>1cm。Villalta评分从治疗前的7.53±0.83降至治疗后的2.06±0.39。血栓直径也从治疗前的1.46±0.16cm降至治疗后的0.35±0.11cm。滤器取出率为88.24%(15/17),滤器平均留置时间为19.25±4.5天。PCDT组共11例患者,4例患者腔内血栓完全溶解,6例患者残留血栓最大直径≤1cm,1例患者残留血栓最大直径>1cm。Villalta评分从治疗前的7.45±0.76降至治疗后的2.09±0.55。血栓直径从治疗前的1.50±0.21cm降至治疗后的0.33±0.35cm,滤器取出率为90.91%(10/11)。
抗凝治疗、CDT和PCDT这三种治疗方法对IVCFT患者术前和术后溶栓及症状改善均有意义。CDT和PCDT的应用优于抗凝治疗,而CDT组和PCDT组之间无显著差异。抗凝治疗组滤器取出率最低,CDT组和PCDT组之间无显著差异。